Northern Ireland Centre for Stratified Medicine, Ulster University, Altnagelvin Hospital, Glenshane Road, Londonderry, United Kingdom.
Northern Ireland Centre for Stratified Medicine, Ulster University, Altnagelvin Hospital, Glenshane Road, Londonderry, United Kingdom.
Osteoarthritis Cartilage. 2018 May;26(5):612-619. doi: 10.1016/j.joca.2018.02.901. Epub 2018 Mar 2.
Osteoarthritis (OA) was previously thought of as 'wear and tear' as humans age, however there is increasing evidence to support an inflammatory theory. The nucleotide-binding and oligomerization domain-like receptor containing protein 3 (NLRP3) inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as Interleukin-1 beta (IL-1β), Tumour necrosis factor alpha (TNF-α) and Matrix metalloproteinase-3 (MMP-3) which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in OA. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for OA could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in OA pathology and how its members could act as potential biomarkers to assist clinical decisions.
骨关节炎（OA）以前被认为是人类衰老时的“磨损”，然而，越来越多的证据支持炎症理论。核苷酸结合寡聚化结构域样受体包含蛋白 3（NLRP3）炎性小体与许多关节炎疾病的发病机制有关，产生促炎细胞因子和降解酶，如白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）和基质金属蛋白酶-3（MMP-3），这些物质可导致软骨退化和滑膜炎症。本综述旨在总结 NLRP3 在 OA 中的作用的证据。目前，治疗选择侧重于疾病的管理，迄今为止尚无治愈方法。新型 OA 生物标志物的开发可能改善诊断、治疗和管理。重要的是，本综述详细介绍了 NLRP3 炎性小体在 OA 病理中的作用，以及其成员如何作为潜在的生物标志物来辅助临床决策。
